Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics

Biological Psychiatry

Volumn 82, Issue 9, 2017, Pages 623-633

  Black, Sarah W ^a   Schwartz, Michael D ^a,b   Chen, Tsui Ming ^a   Hoener, Marius C ^b   Kilduff, Thomas S ^a  

^a SRI INTERNATIONAL   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cataplexy; Hypocretin; Mouse models; Orexin; Sleep; Trace amines

Indexed keywords

PARTIAL AGONIST; RO 5256390; RO 5263397; TRACE AMINE ASSOCIATED RECEPTOR 1 AGONIST; UNCLASSIFIED DRUG; 4-(3-FLUORO-2-METHYLPHENYL)-4,5-DIHYDROOXAZOL-2-YLAMINE; G PROTEIN COUPLED RECEPTOR; OXAZOLE DERIVATIVE; TRACE AMINE-ASSOCIATED RECEPTOR 1; WAKEFULNESS PROMOTING AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CATAPLEXY; CONTROLLED STUDY; ELECTROMYOGRAM; HOMOZYGOSITY; LOCOMOTION; MALE; MOUSE; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; REM SLEEP; SLEEP; WAKEFULNESS; WILD TYPE; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; KNOCKOUT MOUSE; MOTOR ACTIVITY; RARE DISEASE; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOTOR ACTIVITY; NARCOLEPSY; OXAZOLES; RARE DISEASES; RECEPTORS, G-PROTEIN-COUPLED; SLEEP, REM; WAKEFULNESS-PROMOTING AGENTS;

EID: 85007486753     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.10.012     Document Type: Article

References (49)

1. Burgess, C.R., Scammell, T.E., Narcolepsy: Neural mechanisms of sleepiness and cataplexy. J Neurosci 32 (2012), 12305–12311.
2. Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000), 991–997.
3. Thannickal, T.C., Moore, R.Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000), 469–474.
4. Nishino, S., Ripley, B., Overeem, S., Lammers, G.J., Mignot, E., Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000), 39–40.
5. Gerashchenko, D., Murillo-Rodriguez, E., Lin, L., Xu, M., Hallett, L., Nishino, S., et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 184 (2003), 1010–1016.
6. Zhang, S., Lin, L., Kaur, S., Thankachan, S., Blanco-Centurion, C., Yanagisawa, M., et al. The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Neuroscience 148 (2007), 34–43.
7. Chemelli, R.M., Willie, J.T., Sinton, C.M., Elmquist, J.K., Scammell, T., Lee, C., et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98 (1999), 437–451.
8. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999), 365–376.
9. Willie, J.T., Chemelli, R.M., Sinton, C.M., Tokita, S., Williams, S.C., Kisanuki, Y.Y., et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: Molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38 (2003), 715–730.
10. Beuckmann, C.T., Sinton, C.M., Williams, S.C., Richardson, J.A., Hammer, R.E., Sakurai, T., et al. Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci 24 (2004), 4469–4477.
11. Hara, J., Beuckmann, C.T., Nambu, T., Willie, J.T., Chemelli, R.M., Sinton, C.M., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30 (2001), 345–354.
12. Tabuchi, S., Tsunematsu, T., Black, S.W., Tominaga, M., Maruyama, M., Takagi, K., et al. Conditional ablation of orexin/hypocretin neurons: A new mouse model for the study of narcolepsy and orexin system function. J Neurosci 34 (2014), 6495–6509.
13. Burgess, C.R., Tse, G., Gillis, L., Peever, J.H., Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33 (2010), 1295–1304.
14. Guilleminault, C., Cao, M.T., Narcolepsy: Diagnosis and management. Kryger, M.H., Roth, T., Dement, W.C., (eds.) Principles and Practice of Sleep Medicine, 5th ed., 2011, Saunders, St. Louis, 957–968.
15. Wisor, J.P., Nishino, S., Sora, I., Uhl, G.H., Mignot, E., Edgar, D.M., Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21 (2001), 1787–1794.
16. Madras, B.K., Xie, Z., Lin, Z., Jassen, A., Panas, H., Lynch, L., et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319 (2006), 561–569.
17. Nishino, S., Mignot, E., Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52 (1997), 27–78.
18. Mignot, E., Narcolepsy: Pathophysiology and genetic predisposition. Kryger, M.H., Roth, T., Dement, W.C., (eds.) Principles and Practice of Sleep Medicine, 5th ed., 2011, Saunders, St. Louis, 938–956.
19. Bosch, O.G., Quednow, B.B., Seifritz, E., Wetter, T.C., Reconsidering GHB: orphan drug or new model antidepressant?. J Psychopharmacol 26 (2012), 618–628.
20. Boscolo-Berto, R., Viel, G., Montagnese, S., Raduazzo, D.I., Ferrara, S.D., Dauvilliers, Y., Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 16 (2012), 431–443.
21. Borowsky, B., Adham, N., Jones, K.A., Raddatz, R., Artymyshyn, R., Ogozalek, K.L., et al. Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 98 (2001), 8966–8971.
22. Bunzow, J.R., Sonders, M.S., Arttamangkul, S., Harrison, L.M., Zhang, G., Quigley, D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60 (2001), 1181–1188.
23. Lindemann, L., Meyer, C.A., Jeanneau, K., Bradaia, A., Ozmen, L., Bluethmann, H., et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324 (2008), 948–956.
24. Wolinsky, T.D., Swanson, C.J., Smith, K.E., Zhong, H., Borowsky, B., Seeman, P., et al. The trace amine 1 receptor knockout mouse: An animal model with relevance to schizophrenia. Genes Brain Behav 6 (2007), 628–639.
25. Revel, F.G., Meyer, C.A., Bradaia, A., Jeanneau, K., Calcagno, E., Andre, C.B., et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology 37 (2012), 2580–2592.
26. Bradaia, A., Trube, G., Stalder, H., Norcross, R.D., Ozmen, L., Wettstein, J.G., et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A 106 (2009), 20081–20086.
27. Revel, F.G., Moreau, J.L., Gainetdinov, R.R., Bradaia, A., Sotnikova, T.D., Mory, R., et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A 108 (2011), 8485–8490.
28. Espinoza, S., Lignani, G., Caffino, L., Maggi, S., Sukhanov, I., Leo, D., et al. TAAR1 modulates cortical glutamate NMDA receptor function. Neuropsychopharmacology 40 (2015), 2217–2227.
29. Burchett, S.A., Hicks, T.P., The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain. Prog Neurobiol 79 (2006), 223–246.
30. Grandy, D.K., Trace amine-associated receptor 1—family archetype or iconoclast?. Pharmacol Ther 116 (2007), 355–390.
31. Scanlan, T.S., Suchland, K.L., Hart, M.E., Chiellini, G., Huang, Y., Kruzich, P.J., et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10 (2004), 638–642.
32. Kok, S.W., Roelfsema, F., Overeem, S., Lammers, G.J., Frolich, M., Meinders, A.E., et al. Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. Am J Physiol Endocrinol Metab 288 (2005), E892–E899.
33. Berry, M.D., The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev Recent Clin Trials 2 (2007), 3–19.
34. Davis, B.A., Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects. J Chromatogr 466 (1989), 89–218.
35. Sotnikova, T.D., Caron, M.G., Gainetdinov, R.R., Trace amine-associated receptors as emerging therapeutic targets. Mol Pharmacol 76 (2009), 229–235.
36. Revel, F.G., Moreau, J.L., Gainetdinov, R.R., Ferragud, A., Velazquez-Sanchez, C., Sotnikova, T.D., et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry 72 (2012), 934–942.
37. Revel, F.G., Moreau, J.L., Pouzet, B., Mory, R., Bradaia, A., Buchy, D., et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry 18 (2013), 543–556.
38. Schwartz, M.D., Black, S.W., Fisher, S.P., Palmerston, J.B., Morairty, S.R., Hoener, M.C., Kilduff, T.S., Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition. Neuropsychopharmacology 42 (2017), 1305–1314.
39. Fisher, S.P., Schwartz, M.D., Black, S.W., Thomas, A.M., Chen, T.-M., Miller, M.A., et al. Quantitative EEG analysis provides an early-stage indicator of disease onset and progression in the zQ175 knock-in mouse model of Huntington's disease. Sleep 39 (2016), 379–391.
40. Fisher, S.P., Wurts Black, S.W., Schwartz, M.D., Wilk, A.J., Liu, H., Chen, T.-M., et al. Longitudinal analysis of the sleep phenotype and EEG signatures in the R6/2 model of Huntington's disease. Brain 136 (2013), 2159–2172.
41. Black, S.W., Morairty, S.R., Fisher, S.P., Chen, T.M., Warrier, D.R., Kilduff, T.S., Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 36 (2013), 325–336.
42. Black, S.W., Morairty, S.R., Chen, T.M., Leung, A.K., Wisor, J.P., Yamanaka, A., et al. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci 34 (2014), 6485–6494.
43. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13 (2007), 150–155.
44. Weller T, Koberstein R, Aissaoui H, Clozel M, Fischli W, inventors; Actelion Pharm, LTD, asignee. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. WIPO application WO 2005118548. December 15, 2005.
45. Willie, J.T., Renthal, W., Chemelli, R.M., Miller, M.S., Scammell, T.E., Yanagisawa, M., et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 130 (2005), 983–995.
46. Black, S.W., Yamanaka, A., Kilduff, T.S., Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 152 (2017), 89–113.
47. Scammell, T.E., Willie, J.T., Guilleminault, C., Siegel, J.M., A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 32 (2009), 111–116.
48. Hasegawa, E., Yanagisawa, M., Sakurai, T., Mieda, M., Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest 124 (2014), 604–616.
49. Nagahara, T., Saitoh, T., Kutsumura, N., Irukayama-Tomobe, Y., Ogawa, Y., Kuroda, D., et al. Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J Med Chem 58 (2015), 7931–7937.